We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Ticker | Name | Price | Change | Change % | Volume |
---|---|---|---|---|---|
AVTX | Avalo Therapeutics Inc | 20.50 | 15.75 | 331.58% | 1,711,730 |
XLO | Xilio Therapeutics Inc | 2.03 | 1.39 | 217.68% | 7,461,635 |
BCG | Binah Capital Group Inc | 18.52 | 9.02 | 94.95% | 177,890 |
PIK | Kidpik Corporation | 6.07 | 2.80 | 85.63% | 2,608,677 |
AKAN | Akanda Corporation | 0.27 | 0.1051 | 63.74% | 6,123,245 |
PEGR | Project Energy Reimagined Acquisition Corporation | 11.58 | 2.92 | 33.72% | 460 |
MTEM | Molecular Templates Inc | 3.07 | 0.71 | 30.08% | 99,484 |
KTRA | Kintara Therapeutics Inc | 0.113 | 0.0235 | 26.26% | 17,188,731 |
JCSE | JE Cleantech Holdings Limited | 0.882 | 0.1419 | 19.17% | 10 |
LGVN | Longeveron Inc | 3.70 | 0.59 | 18.97% | 3,943 |
ATLX | Atlas Lithium Corporation | 17.66 | 2.74 | 18.36% | 10,946 |
Gilead Sciences, Inc. (Nasdaq: GILD) and Xilio Therapeutics, Inc. (Nasdaq: XLO) today announced an exclusive license agreement to develop and commercialize Xilio’s Phase 1 tumor-activated IL-12 program, XTX301.
Kidpik Corp. (NASDAQ: PIK) ("kidpik” or the "Company"), an online clothing subscription-based e-commerce company, today announced that the Company received written notification from the Listing Qualification Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that is has regained full compliance with the Minimum Bid Price Requirement.
SAN DIEGO, March 27, 2024 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced the expansion of the inclusion criteria in the open label 15- patient REM-001 study in cutaneous metastatic breast cancer (CMBC) to include patients receiving pembrolizumab (KEYTRUDA®) for at least three months at screening.
PLYMOUTH MEETING, Pa., March 26, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that Dr. Jacqueline Shea, President and CEO will participate in The Novel Therapeutics Forum hosted by Citizens JMP at Penn Medicine at 10:00 am ET on April 2, 2024.
Ticker | Name | Price | Change | Change % | Market Cap | Volume |
---|---|---|---|---|---|---|
BTC | Bitcoin | 70,382.42 | 917.85 | 1.32% | 1.38T | 7,376,737,190 |
ETH | Ethereum | 3,564.03 | 63.97 | 1.83% | 429.61B | 3,937,733,128 |
USDT | Tether USD | 0.99936 | -0.00008 | -0.01% | 97.8B | 1,037,898,827 |
BNB | Binance Coin | 582.91 | 8.78 | 1.53% | 92.28B | 517,323,115 |
SOL | Solana | 183.84 | -2.28 | -1.23% | 81.33B | 1,821,036,200 |
STETH | stETH | 3,554.67 | 90.24 | 2.60% | 34.95B | 13,509,541 |
XRP | Ripple | 0.6192 | 0.0077 | 1.26% | 33.83B | 598,304,485 |
DOGE | Dogecoin | 0.21843 | 0.02847 | 14.98% | 31.57B | 2,190,603,403 |
USDC | USD Coin | 0.99998 | -0.00002 | 0.00% | 28.07B | 1,500,108,899 |
ADA | Cardano | 0.6471 | -0.0005 | -0.08% | 22.85B | 201,979,539 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions